E-Mail
NEW YORK, NY (March 1, 2021) By harnessing the immune system against cancer, immunotherapies have revolutionized the way some types of cancer are treated. But most patients across cancer types do not respond, and in most cases, scientists are at a loss as to why.
Researchers at Columbia and MIT have created a new technique that can uncover nearly all of the tricks cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments.
The researchers tested their new technique with cancer cells and matching immune cells from melanoma patients and identified previously unknown resistance mechanisms to immune checkpoint inhibitors, a powerful and widely used class of immunotherapy drugs.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine
January 26, 2021 GMT
NEW YORK & AMSTERDAM (BUSINESS WIRE) Jan 26, 2021
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company’s co-founder, Board member and Chairman of its Scientific Advisory Board, Ton Schumacher, Ph.D., has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. Awarded each year by the Louis-Jeantet Foundation to leading-edge researchers who are active in the member states of the Council of Europe, the prize is intended to foster scientific excellence and encourage the continuation of innovative research projects.
(1)
Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company s co-founder, Board member and Chairman of its Scientific Advisory Board, Ton Schumacher, Ph.D., has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. Awarded each year by the Louis-Jeantet Foundation to leading-edge researchers who are active in the member states of the Council of Europe, the prize is intended to foster scientific excellence and encourage the continuation of innovative research projects.
Ellodi Pharmaceuticals Welcomes Dr. David Kessler and John Fraher to its Board of Directors
Ellodi Pharmaceuticals Welcomes Dr. David Kessler and John Fraher to its Board of Directors Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company formed by TPG Capital, today announced that David Kessler, M.D., and John Fraher have joined the companys newly established Board of Directors. Dr. Kessler and Fraher will serve on the companys inaugural board alongside CEO Troy Hamilton and three members of the TPG Capital team: John Schilling, M.D., Todd Sisitsky, and Katherine Wood. The formation of the board follows the recent creation of Ellodi Pharmaceuticals, which was established in September 2020 through a transaction that spun-out select clinical assets from Adare Pharmaceuticals. Launched in partnership with former members of Adares clinical leadership team, Ellodi Pharmaceuticals is dedicated to the continued development of APT-1011, a novel therapy in
BioSpace Announces Top New Life Sciences Companies to Watch in 2021
News provided by
Share this article
Share this article
DES MOINES, Iowa, Jan. 6, 2021 /PRNewswire/ BioSpace, Inc., the leading life sciences news and careers site, has announced their 25 selections for biopharma s most promising up-and-coming companies in 2021.
For the past seven years, BioSpace has been honoring the most innovative new biopharma companies from across the U.S. The
NextGen Bio list has been noted for anticipating organizations on their way to success.
Topping the
NextGen Bio Class of 2021 list is Sana Biotechnology, developer of accessible gene and cell therapy solutions. Having raised $700 million in June, Sana has since acquired Oscine Corp